Janus Henderson Group PLC bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 194,116 shares of the medical instruments supplier’s stock, valued at approximately $18,348,000. Janus Henderson Group PLC owned approximately 0.26% of West Pharmaceutical Services at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. American Century Companies Inc. raised its stake in West Pharmaceutical Services by 0.4% during the second quarter. American Century Companies Inc. now owns 701,364 shares of the medical instruments supplier’s stock worth $66,293,000 after acquiring an additional 2,605 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in West Pharmaceutical Services by 16.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 88,252 shares of the medical instruments supplier’s stock worth $8,342,000 after acquiring an additional 12,609 shares in the last quarter. CIBC Asset Management Inc acquired a new position in West Pharmaceutical Services during the second quarter worth $223,000. Chatham Capital Group Inc. raised its stake in West Pharmaceutical Services by 7.8% during the second quarter. Chatham Capital Group Inc. now owns 17,300 shares of the medical instruments supplier’s stock worth $1,635,000 after acquiring an additional 1,245 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in West Pharmaceutical Services by 149.6% during the second quarter. Prudential Financial Inc. now owns 400,270 shares of the medical instruments supplier’s stock worth $37,834,000 after acquiring an additional 239,906 shares in the last quarter. Institutional investors and hedge funds own 90.70% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/janus-henderson-group-plc-invests-18-35-million-in-west-pharmaceutical-services-inc-wst/1643198.html.

West Pharmaceutical Services, Inc. (NYSE WST) opened at 92.28 on Friday. West Pharmaceutical Services, Inc. has a 1-year low of $70.17 and a 1-year high of $99.91. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of 39.61 and a beta of 1.12. The firm’s 50-day moving average price is $93.42 and its 200 day moving average price is $91.55.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The firm had revenue of $397.60 million during the quarter, compared to analysts’ expectations of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.59 EPS. On average, analysts predict that West Pharmaceutical Services, Inc. will post $2.67 EPS for the current year.

WST has been the subject of several recent analyst reports. Jefferies Group LLC upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.00 to $115.00 in a research note on Friday, September 15th. Stephens initiated coverage on West Pharmaceutical Services in a research note on Tuesday, October 3rd. They set an “equal weight” rating and a $99.00 price objective for the company. Zacks Investment Research upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. BidaskClub lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Finally, Bank of America Corporation lowered West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $104.00.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.